title: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.
abstract: The development of end-stage renal disease (ESRD) in patients with sickle-cell anaemia results in increased transfusion dependence, increasing the risk of iron overload. Correction of anaemia with recombinant human erythropoietin (rHuEpo) in dialysis patients might also result in stimulation of haemoglobin F production, which protects against sickling, although very high doses were required to achieve this effect in non-uraemic animals. rHuEpo was administered to three transfusion-dependent patients with ESRD and homozygous sickle-cell disease (initial dose 100 U/kg twice weekly, increasing to 125 U/kg at 6 weeks, and to 150 U/kg at 9 weeks in two patients). This resulted in reticulocytosis and increased circulating erythroid blast-forming units. Total haemoglobin was predominantly HbA (i.e. transfused blood) at the start of the study, reflecting transfusion dependence, but after 3 months' treatment was between 60 and 94% HbS. No sickling crises occurred. Haemoglobin F remained at less than 3% of total haemoglobin. One patient was withdrawn at 10 weeks with CAPD peritonitis. The other two patients completed 12 weeks' treatment without transfusion but final Hb concentrations were 4.5 and 5.5 g/dl. Whether larger doses of rHuEpo will be more successful in managing such patients remains unclear. No effect on HbF production can be expected.
authors.affiliation: Department of Nephrology, Leicester General Hospital, UK.
authors.forename: C R
authors.initials: CR
authors.lastname: Tomson
authors.forename: M E
authors.initials: ME
authors.lastname: Edmunds
authors.forename: K
authors.initials: K
authors.lastname: Chambers
authors.forename: S
authors.initials: S
authors.lastname: Bricknell
authors.forename: J
authors.initials: J
authors.lastname: Feehally
authors.forename: J
authors.initials: J
authors.lastname: Walls
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy; D001803:Blood Transfusion; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D006454:Hemoglobins / Q000096:biosynthesis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin